Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults
NCT07233330Phase 2Not yet recruiting
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2026
- Primary completion
- Mar 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in Idiopathic nephrotic syndrome (INS), sponsored by Mario Negri Institute for Pharmacological Research. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT07233330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233330.